November 15, 2024

New vaccines offer hope for brain tumor patients

New vaccines offer hope for brain tumor patients

Michael Platten is the winner of the “Breakthrough of the Year 2024” in the Life Sciences category of the Falling Walls Foundation.

Michael Platten’s research has a major goal: He wants to advance the cure of one of the deadliest forms of brain tumors, known as gliomas. His work has shown that the immune system of patients can be mobilized with the help of novel vaccines against this form of cancer. The body’s own defenses are then able to take very precise action against modified proteins that drive tumor growth. Michael Platten will be honored for his groundbreaking findings with the “Breakthrough of the Year 2024” award from the Falling Wall Foundation in Berlin on November 9, 2024.

Platten is head of the Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology at the German Cancer Research Center (DKFZ) and director of the Department of Neurology at the University Medical Center Mannheim (UMM). Since October, Platten has also been president of the European Association of Neuro-Oncology (EANO).

His involvement in clinical practice is an essential element of Platten’s scientific success: “My inspiration comes primarily from the patients who struggle with this devastating disease every day,” says Platten. He believes it is of central importance that scientists develop solutions that bring real, tangible improvements to people’s lives, the cancer researcher continues.

Breaking the wall of brain tumor vaccines
Clinical trials have already confirmed that his idea of activating the immune system with the help of vaccines against tumor cells works. In these trials, the vaccines proved to be safe and effective. The proof that his vaccine can trigger a targeted immune response in a patient’s brain tumor was a breakthrough moment for him, says Platten.

Precision tumor therapy
What makes Platten’s findings so special is the precision with which the immune system can attack cancer cells after activation by the novel vaccines: it recognizes tiny differences between normal proteins and those with cancer-causing mutations in their blueprint. His team has discovered that the so-called IDH1 mutation in particular plays a key role in many gliomas. This mutation occurs in almost 70 percent of low-grade, or slow-growing, gliomas.
The immunotherapy developed by Platten targets precisely this IDH1 mutation in order to generate a broad and effective immune response that encompasses all tumor cells, even if they differ genetically from one another. Cancer cells can thus be eliminated very specifically.

Application not only against brain tumors
Using advanced bioinformatics and molecular biology tools, his team has developed specific cellular immunotherapies that can potentially be used not only against brain tumors but also against other types of cancer. The idea behind this is that the identified mutations are present in all of a patient’s tumor cells, which is crucial for the vaccines to be effective.
Platten also wants his research to inspire the next generation of scientists. His advice to young researchers is: “Be brave, ask questions, work in teams and share your knowledge. And if necessary, don’t be afraid to break into completely new fields of research.”

Falling Walls Science Summit 2024
The title “Falling Walls Science Breakthrough of the Year” is awarded annually. It recognizes the most significant scientific breakthroughs in various categories of the Falling Walls Global Call. The winners present their groundbreaking work to a global audience at the Falling Walls Science Summit in Berlin on November 9, 2024.

Michael Platten is one of ten winners in the Life Sciences category and ultimately the winner of the Breakthrough of the Year 2024 in the Life Sciences.
His lecture can be followed online on November 9 from 5:15 to 5:30 p.m.:
https://falling-walls.com/foundation/people/michael-platten

The Falling Walls Science Summit will focus on topics such as artificial intelligence, renewable energies, quantum research and science diplomacy. Of particular importance is the question of how scientific breakthroughs can help to overcome the major global challenges of our time – climate change, health crises and technological upheaval.

The Berlin-based Falling Walls Foundation aims to bring together people “who want to tear down the next walls in science and society”. Since the first conference on the 20th anniversary of the fall of the Berlin Wall in 2009, Falling Walls has developed into a constantly growing network of the most ambitious and forward-thinking minds from around the world.

Our latest News

discover more
RHEACELL receives EMA approval for allo-APZ2-CVU Phase 3 trial in chronic venous ulcers

RHEACELL receives EMA approval for allo-APZ2-CVU Phase 3 trial in chronic venous ulcers

Heidelberg, Germany, 19.12.2024 – RHEACELL today received approval from the European Medicines Agency (EMA) for its blinded, multi-centric Phase-3 trial (NCT06489028) evaluating allo-APZ2-CVU in patients with chronic venous ulcers (CVU). The pivotal trial will be conducted at more than 100 sites and is expected to enroll 250 patients, starting enrollment in Europe in Q1 2025. […]

Common cough syrup ingredient shows promise in treating serious lung disease

Common cough syrup ingredient shows promise in treating serious lung disease

EMBL scientists discover that an FDA-approved, over-the-counter cough syrup ingredient has potential to treat fibrotic lung disease. Summary A common over-the-counter ingredient in many cough syrups may have a greater purpose for people suffering from lung fibrosis that is related to any number of serious health conditions.  Scientists from EMBL Heidelberg were part of a […]

Antibody that Neutralizes Inhibitory Factors Involved in Nerve Regeneration Leads to Enhanced Motor Function after Acute Spinal Cord Injury

Antibody that Neutralizes Inhibitory Factors Involved in Nerve Regeneration Leads to Enhanced Motor Function after Acute Spinal Cord Injury

Antibodies can improve the rehabilitation of people with acute spinal cord injury. Researchers at 13 clinics in Germany, Switzerland, the Czech Republic and Spain have investigated this with promising results. For the first time, it was possible to identify patient groups that displayed a clinically relevant treatment effect. A follow-up study will start in December […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp